Details of 14 cases of patients with PRCA treated with daratumumab in the Netherlands
| No. . | Age . | Sex . | Underlying disease . | Donor type and match grade . | Stem cell source . | Conditioning intensity∗ . | AB0-titer† before treatment . | Donor chimerism . | Prior treatment . | Start daratumumab after SCT (d) . | Total number of doses given (7 day interval‡) . | Number of doses given at reticulocytosis§ . | Iso-hemaglutinnin disappeared . | Reported side-effects . | Ongoing response (d) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 63 | M | AML | MUD 10/10 | Peripheral blood | MAC | 1:16 Anti-A | T 100% nT 100% | Rituximab + DLI | 108 | 2 | 2 | Yes | None reported | 405 |
| 2 | 56 | M | MDS | MUD 10/10 | Peripheral blood | MAC | 1:128 Anti-A | T 98% nT 96% | Steroids + Rituximab | 140 | 5‡ | 5 | Yes | PML (death) | 191|| |
| 3 | 63 | M | PMF | MUD 9/10 | Peripheral blood | MAC | 1:32 Anti-B | T 100% nT 100% | Rituximab + DLI | 121 | 2‡ | 2 | Yes | None reported | 294 |
| 4 | 28 | M | Sickle cell disease | SIB 10/10 | Peripheral blood | NMA | 1:32 Anti-B | T 69% nT 100% | Rituximab | 60 | 4 | 3 | Yes | None reported | 456 |
| 5 | 61 | F | AML | MUD 10/10 | Peripheral blood | MAC | 1:512 Anti-A | Whole blood 100% | None | 210 | 2 | 2 | Yes | None reported | 383 |
| 6 | 60 | F | AML | MUD 10/10 | Peripheral blood | MAC | 1:64 Anti-A | Whole blood >95% | Rituximab | 460 | 6 | 4 | Yes | None reported | 1045 |
| 7 | 55 | M | AML | MUD 10/10 | Peripheral blood | RIC | 1:512 Anti-A | Whole blood >95% | Rituximab + DLI + BOR | 2898 | 4 | 2 | Yes | None reported | 957 |
| 8 | 45 | F | AML | MUD 10/10 | Peripheral blood | MAC | 1:16 Anti-A + B | T 99% nT 100% | None | 176 | 3 | 2 | Yes | Infuse reaction | 389 |
| 9 | 55 | F | MDS | MUD 10/10 | Peripheral blood | RIC | 1:128 Anti-A | T 96% nT 100% | None | 111 | 6 | 1 | Yes | None reported | 229 |
| 10 | 61 | M | MDS | SIB 10/10 | Peripheral blood | MAC | 1:512 Anti-A | T 99% nT 100% | None | 123 | 4 | 2 | Yes | None reported | 700 |
| 11 | 60 | M | AML | MUD 9/10 | Peripheral blood | RIC | 1:128 Anti-A | Whole blood 100% | DLI | 391 | 1 | 1 | Yes | None reported | 219 |
| 12 | 46 | M | AML | MUD 10/10 | Peripheral blood | RIC | 1:256 Anti-A | Whole blood >95% | None | 136 | 4 | 2 | Yes | None reported | 126 |
| 13 | 45 | M | AML | MUD 10/10 | Peripheral blood | MAC | 1:128 Anti-A | Whole blood > 95% | None | 160 | 4 | 3 | Yes | None reported | 105 |
| 14 | 58 | M | T-cell lymphoma¶ | MUD 10/10 | Peripheral blood | MAC | 1:512 Anti-A | Whole blood 99% | DLI | 123 | 4‡ | - | No | None reported | - |
| No. . | Age . | Sex . | Underlying disease . | Donor type and match grade . | Stem cell source . | Conditioning intensity∗ . | AB0-titer† before treatment . | Donor chimerism . | Prior treatment . | Start daratumumab after SCT (d) . | Total number of doses given (7 day interval‡) . | Number of doses given at reticulocytosis§ . | Iso-hemaglutinnin disappeared . | Reported side-effects . | Ongoing response (d) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 63 | M | AML | MUD 10/10 | Peripheral blood | MAC | 1:16 Anti-A | T 100% nT 100% | Rituximab + DLI | 108 | 2 | 2 | Yes | None reported | 405 |
| 2 | 56 | M | MDS | MUD 10/10 | Peripheral blood | MAC | 1:128 Anti-A | T 98% nT 96% | Steroids + Rituximab | 140 | 5‡ | 5 | Yes | PML (death) | 191|| |
| 3 | 63 | M | PMF | MUD 9/10 | Peripheral blood | MAC | 1:32 Anti-B | T 100% nT 100% | Rituximab + DLI | 121 | 2‡ | 2 | Yes | None reported | 294 |
| 4 | 28 | M | Sickle cell disease | SIB 10/10 | Peripheral blood | NMA | 1:32 Anti-B | T 69% nT 100% | Rituximab | 60 | 4 | 3 | Yes | None reported | 456 |
| 5 | 61 | F | AML | MUD 10/10 | Peripheral blood | MAC | 1:512 Anti-A | Whole blood 100% | None | 210 | 2 | 2 | Yes | None reported | 383 |
| 6 | 60 | F | AML | MUD 10/10 | Peripheral blood | MAC | 1:64 Anti-A | Whole blood >95% | Rituximab | 460 | 6 | 4 | Yes | None reported | 1045 |
| 7 | 55 | M | AML | MUD 10/10 | Peripheral blood | RIC | 1:512 Anti-A | Whole blood >95% | Rituximab + DLI + BOR | 2898 | 4 | 2 | Yes | None reported | 957 |
| 8 | 45 | F | AML | MUD 10/10 | Peripheral blood | MAC | 1:16 Anti-A + B | T 99% nT 100% | None | 176 | 3 | 2 | Yes | Infuse reaction | 389 |
| 9 | 55 | F | MDS | MUD 10/10 | Peripheral blood | RIC | 1:128 Anti-A | T 96% nT 100% | None | 111 | 6 | 1 | Yes | None reported | 229 |
| 10 | 61 | M | MDS | SIB 10/10 | Peripheral blood | MAC | 1:512 Anti-A | T 99% nT 100% | None | 123 | 4 | 2 | Yes | None reported | 700 |
| 11 | 60 | M | AML | MUD 9/10 | Peripheral blood | RIC | 1:128 Anti-A | Whole blood 100% | DLI | 391 | 1 | 1 | Yes | None reported | 219 |
| 12 | 46 | M | AML | MUD 10/10 | Peripheral blood | RIC | 1:256 Anti-A | Whole blood >95% | None | 136 | 4 | 2 | Yes | None reported | 126 |
| 13 | 45 | M | AML | MUD 10/10 | Peripheral blood | MAC | 1:128 Anti-A | Whole blood > 95% | None | 160 | 4 | 3 | Yes | None reported | 105 |
| 14 | 58 | M | T-cell lymphoma¶ | MUD 10/10 | Peripheral blood | MAC | 1:512 Anti-A | Whole blood 99% | DLI | 123 | 4‡ | - | No | None reported | - |
AML, acute myeloid leukemia; BOR, bortezomib; DLI, donor lymphocyte infusion; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; MUD, matched unrelated donor; NMA, nonmyeloablative conditioning; PMF, primary myelofibrosis; PML, progressive multifocal leukoencephalopathy; RIC, reduced intensity conditioning; SIB, matched related donor; T/nT, T cell/non–T-cell chimerism.
For details of the conditioning regimen, see supplemental Table 1.
Highest titer reported, for additional information about Ig subclass see supplemental Table 2.
In 3 patients the dose interval of daratumumab was 14 days.
Reticulocytosis is defined as recovery of normal values of absolute reticulocyte count (>25 × 109/L).
At time of death (day 191), ongoing response.
Hepatosplenic T-cell lymphoma.